Physician profile
Eduardo Braun
NPI 1144486309
$38,561.48
in general payments reported to CMS, 2019-2025
57 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $17K · 2021: $251 · 2022: $928 · 2023: $826 · 2024: $6,419 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,873 · Consulting Fee: $4,395 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,873.37 |
| Consulting Fee | $4,395.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $10,836.44 | 2019-2025 | Venclexta, Alecensa, Tecentriq |
| Astrazeneca Pharmaceuticals Lp | $10,687.03 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Eisai INC. | $3,605.94 | 2020-2025 | |
| Beigene USA, INC. | $2,982.57 | 2024 | Brukinsa |
| Glaxosmithkline, LLC. | $2,383.97 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $1,948.98 | 2020-2025 | Reblozyl, Pomalyst |
| Janssen Scientific Affairs, LLC | $1,617.06 | 2024 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $434.69 | 2020-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $403.27 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Gilead Sciences, INC. | $376.83 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $241.37 | 2022-2025 | Erleada, Rybrevant |
| Astellas Pharma US INC | $239.48 | 2022-2025 | Xtandi, Padcev |
| Genzyme Corporation | $219.41 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $211.17 | 2024-2025 | |
| Pfizer INC. | $172.49 | 2024-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.